Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01430416 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
A Phase 1 study of Uveal Melanoma, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 153
- Enrollment target
- 5
- Study locations
NCT01430416 is a Phase 1 study of Uveal Melanoma that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 153 participants, roughly in line with the 140-participant average among 29 other Uveal Melanoma trials with a reported enrollment target. The trial reports 5 study locations across 3 states.
The verdict
NCT01430416, a Phase 1 study of Uveal Melanoma, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 153 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study has two parts, dose escalation and dose expansion. For dose escalation, the primary objective is to estimate the maximum tolerated dose (MTD) of AEB071 in patients with uveal melanoma. For dose expansion, the primary objective is to characterize the safety and tolerability of the MTD of AEB071 in patients with uveal melanoma.
Conditions Studied
Interventions
- DRUG AEB071
Study Locations (5)
Other
- Novartis Investigative Site - Paris
- Novartis Investigative Site - Leiden
- Novartis Investigative Site - London
Massachusetts
- Dana Farber Cancer Institute DFCI - Brookline - Boston
New York
- Memorial Sloan Kettering MSKCC 4 - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2011-12-20 |
| Est. Completion | 2019-05-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01430416
The ClinicalTrials.gov registry entry for NCT01430416 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 140-participant average among 29 other Uveal Melanoma trials with a reported enrollment target. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Uveal Melanoma appearing as the primary indexed condition, and to 1 intervention - of which AEB071 is the first listed.
NCT01430416 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Other, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT01430416 about?
NCT01430416 is a clinical study titled "Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients". This study has two parts, dose escalation and dose expansion. For dose escalation, the primary objective is to estimate the maximum tolerated dose (MTD) of AEB071 in patients with uveal melanoma. For dose expansion, the primary objective is to characterize the safety and tolerability of the MTD of A...
What is the current status of trial NCT01430416?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 153 participants. The study started on 2011-12-20. Estimated completion is 2019-05-22.
What conditions does trial NCT01430416 study?
This clinical trial studies the following conditions: Uveal Melanoma.
What interventions are being tested in trial NCT01430416?
The interventions under investigation include: AEB071 (DRUG).
Who is sponsoring clinical trial NCT01430416?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01430416 being conducted?
This trial has 5 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma
RECRUITING · Phase 1
-
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
ACTIVE NOT RECRUITING · Phase 1
-
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.